← Leaderboards
Javier Guillermo Blanco
State University Of New York At Buffalo
$5,082,408
Attributed
$5,082,408
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $505.4K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$5,082,408 · 4
By mechanism
R01$4,089,098 · 1
R21$836,157 · 2
R03$157,153 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsVariantBaseGenesDaunorubicinAnthracyclinesSamplingDoxorubicinAlcohol OxidoreductasesCardiotoxicityTissuesProteinsMetabolismMolecularPharmacodynamicsDesignTissue SampleMediatingGeneticAlcoholsMalignant NeoplasmsGenetic VariantPhenotypePathogenesis
Grant awards (21)
Evaluation of myocardial targets to prevent anthracycline cardiotoxicity in children with Down Syndrome and Leukemia$239,250
R21 · FY2020 · CA · contact PI
Evaluation of myocardial targets to prevent anthracycline cardiotoxicity in children with Down Syndrome and Leukemia$199,375
R21 · FY2019 · CA · contact PI
Defining the Contribution of Cellular Hypoxia to the Cardiotoxicity of Anticancer Anthracyclines and Trastuzumab$159,500
R01 · FY2019 · GM · contact PI
Contribution of CBRs and AKRs to the Pharmacodynamics of Anthracycline Drugs$306,171
R01 · FY2018 · GM · contact PI
Epigenetic Regulation of FcRn Expression in Human Lung and its Role in the Disposition of Monoclonal Antibody Drugs$198,751
R21 · FY2018 · HD · contact PI
Contribution of CBRs and AKRs to the Pharmacodynamics of Anthracycline Drugs$306,577
R01 · FY2017 · GM · contact PI
Epigenetic Regulation of FcRn Expression in Human Lung and its Role in the Disposition of Monoclonal Antibody Drugs$198,781
R21 · FY2017 · HD · contact PI
Contribution of CBRs and AKRs to the Pharmacodynamics of Anthracycline Drugs$305,345
R01 · FY2016 · GM · contact PI
Contribution of CBRs and AKRs to the Pharmacodynamics of Anthracycline Drugs$320,817
R01 · FY2015 · GM · contact PI
Characterization of Cardiac Mitochondrial DNA in Donors with Down Syndrome$77,653
R03 · FY2015 · HD · contact PI
Characterization of Cardiac Mitochondrial DNA in Donors with Down Syndrome$79,500
R03 · FY2014 · HD · contact PI
Pharmacogenetics of Human Carbonyl Reductases$302,846
R01 · FY2013 · GM · contact PI
Pharmacogenetics of Human Carbonyl Reductases$313,830
R01 · FY2012 · GM · contact PI
Pharmacogenetics of Human Carbonyl Reductases$313,830
R01 · FY2011 · GM · contact PI
Pharmacogenetics of Human Carbonyl Reductases$317,000
R01 · FY2010 · GM · contact PI
PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES$270,516
R01 · FY2009 · GM · contact PI
PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES$68,339
R01 · FY2009 · GM · contact PI
PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES$270,516
R01 · FY2008 · GM · contact PI
PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES$270,516
R01 · FY2007 · GM · contact PI
PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES$278,595
R01 · FY2006 · GM · contact PI
PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES$284,700
R01 · FY2005 · GM